Diabetes, obesity and osteoporosis are growing health issues in western countries. The Molecular Physiology Research Unit aims to understand the molecular and physiological mechanisms underlying these metabolic disorders, with the long-term goal of developing novel therapeutic approaches.
The team is also more generally interested in identifying and characterizing new inter-organ relationships implicated in normal physiology or in pathological conditions.
For instance, the current research focus includes characterizing the biological roles of vitamin K in glucose homeostasis and metabolism, in bone health and in coagulation, and understanding the functions of osteocalcin, a recently identified hormone produced by bones that affects energy metabolism.
- Director, Molecular Physiology Research Unit, IRCM
- Associate IRCM Research Professor
- Associate Research Professor, Department of Medicine (accreditation in molecular biology, and in biochemistry and molecular medicine), Université de Montréal
- Canada Research Chair holder in Bone and Energy Metabolism
- Adjunct Professor, Department of Medicine, Division of Experimental Medicine, McGill University
- Member, Montreal Diabetes Research Center
- Member, CMDO
- Member, RSBO
Awards and honours
- Étoiles Effervescence Award 2019
- 2017 Pierre-Bois Excellence Award, IRCM Foundation
- 2014 Early Investigators Award, Endocrine Society
- Helmsley Charitable Trust Abstract Award in type 1 diabetes (2014), Endocrine Society
- The Endocrine Society Outstanding Abstract Award (2013), Endocrine Society
- K99/R00 Pathway to Independence Award 2012-2013, National Institute of Diabetes and Digestive and Kidney Diseases
- ASBMR John Haddad Young Investigator Award 2011
Degrees and relevant experience
- B.Sc., Department of Biochemistry, Université de Montréal (1998)
- PhD in molecular biology, Department of Medicine, Université de Montréal (2006)
- Postdoctoral fellowship, Department of Genetics and Development, Columbia University, New York, USA (2006-2011)
- Research Associate, Department of Genetics and Development, Columbia University, New York, USA (2011-2013)
2017: Identification of furin proprotein convertase as a key regulator of bone endocrine function
2017: Link between osteocalcin carboxylation and insulin resistance in humans
2015: Role of gamma-carboxylation in bone endocrine function
2013: Demonstration that osteoclasts regulate glucose metabolism in vivo
Carter S, Miard S, Caron A, Sallé-Lefort S, St-Pierre P, Anhê FF, Lavoie-Charland E, Blais-Lecours P, Drolet MC, Lefebvre JS, Lacombe J, Deshaies Y, Couet J, Laplante M, Ferron M, Bossé Y, Marette A, Richard D, Marsolais D, Picard F, Loss of OcaB Prevents Age-Induced Fat Accretion and Insulin Resistance by Altering B-Lymphocyte Transition and Promoting Energy Expenditure. - Diabetes 2018 Jul
Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galán-Díez M, Lacampagne A, Mitchell SJ, Mattison JA, Chen Y, Bacchetta J, Szulc P, Kitsis RN, de Cabo R, Friedman RA, Torsitano C, McGraw TE, Puchowicz M, Kurland I, Karsenty G, Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise. - Cell Metabolism 2017 Jan 10
Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galán-Díez M, Lacampagne A, Mitchell SJ, Mattison JA, Chen Y, Bacchetta J, Szulc P, Kitsis RN, de Cabo R, Friedman RA, Torsitano C, McGraw TE, Puchowicz M, Kurland I, Karsenty G, Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise. - Cell Metabolism 2016 Jun 14
ICI Première (Les années lumières) – Mathieu Ferron explains why our bones help regulate appetite.
Radio-Canada - A team led by Mathieu Ferron has uncovered the mechanism that allows bones to respond to sugar in our blood.
ICI Première (Médium large) - Mathieu Ferron's team has demonstrated how osteocalcin, a hormone produced by our bones that could influence the development of diabetes in some people, is activated before being released into the bloodstream.
- Diabète Québec (2017)
- Natural Sciences and Engineering Research Council of Canada (2016-2021)
- Canadian Institutes of Health Research (2013-2019) (2018-2023)
- Canada Research Chair tier 2 (2013-2018)
- J.A. de Sève Foundation (2014-2016)
- Diabète Québec-MDRC (2014)
- John R. Evans Leaders Fund, Canada Foundation for Innovation (2013)